RecruitingPhase 1NCT05320107

The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects

Unraveling the Aesthetic Mind in Anhedonia, Insights From Pharmacological Imaging of the Human Brain: A Single-blind, Randomized, Placebo-controlled Cross-over Study


Sponsor

Medical University of Vienna

Enrollment

60 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to assess the impact of ketamine on aesthetic perception and processing. This study assesses the role of these effects in facilitating ketamine's antidepressant properties, with a focus on anhedonia. To address this aim, 25 patients with major depressive disorder and 35 healthy controls will be assessed twice with magnetic resonance imaging, once after administration of intravenous ketamine (subanesthetic dose) and once after administration of placebo.This study has a single-center, placebo-controlled, cross-over study design. During MRI, structural, resting state, and functional imaging will be performed. Functional imaging will comprise aesthetic processing, reward, and sexual arousal paradigms. In addition, various neuropsychological scales assessing depressive symptoms, anhedonia, and aesthetic processing will be performed. Eligibility for participation will be assessed during a screening visit, a follow up visit will end study participation.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how a single low dose of ketamine (an anesthetic used at low doses as an antidepressant) affects mood and brain activity in people with depression, to understand why it works so quickly compared to standard antidepressants. **You may be eligible if...** - You have a diagnosis of depression - You are between 18 and 65 years old - You are not currently responding well to standard antidepressants - You have no history of psychosis or ketamine abuse **You may NOT be eligible if...** - You have a history of schizophrenia or psychosis - You have a substance use disorder, including ketamine misuse - You are pregnant or breastfeeding - You have uncontrolled heart disease or high blood pressure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study

DRUGPlacebo

0.9% NaCl


Locations(1)

Medical University of Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05320107


Related Trials